Anti-CD20 antibody (Rituximab) therapy in a myasthenia gravis patient with follicular lymphoma [2]

Annals of Hematology

Volumn 84, Issue 8, 2005, Pages 548-550

  Takagi, Kazutaka ^a   Yoshida, Akira ^a   Iwasaki, Hiromichi ^a   Inoue, Hitoshi ^b   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b National Hospital Organization   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CHOLINERGIC RECEPTOR ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERLEUKIN 2 RECEPTOR; PREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; VINCRISTINE;

ADULT; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BLOOD TOXICITY; CASE REPORT; CLINICAL FEATURE; DRUG MECHANISM; FOLLICULAR LYMPHOMA; HUMAN; LETTER; LYMPHADENOPATHY; MALE; MYASTHENIA GRAVIS; PLASMAPHERESIS; PRIORITY JOURNAL; THYMECTOMY;

ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC;

EID: 22344445127     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-1050-4     Document Type: Letter

References (5)

1. Gajra A, Grethlein SJ (2000) Response of myasthenia gravis to rituximab in a patient with lymphoma: First report. Blood 96(11):237b
2. Rastetter W, Molina A, White CA (2004) Rituximab: Expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 55:477-503 10.1146/annurev.med.55.091902.104249
3. Silverman GJ, Weisman S (2003) Rituximab therapy and autoimmune disorders: Prospects for anti-B cell therapy. Arthritis Rheum 48(6):1484-1492 10.1002/art.10947
4. Wylam ME, Anderson PM, Kuntz NL, Rodriguez V (2003) Successful treatment of refractory myasthenia gravis using rituximab: A pediatric case report. J Pediatr 143(5):674-677 10.1067/S0022-3476(03)00300-7
5. Zaja FF, Russo DD, De Vita SS, Sperotto AA, Patriarca FF, Michelutti AA, Fanin RR (2001) Rituximab for the treatment of autoimmune disease. Blood 98(11):41b 10.1182/blood.V98.1.41